TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27894522

Group type: EXPERIMENTAL
Intervention: Nickel-free braces
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional braces
Number of subjects: 42
Study: 26111700

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) plus standardised medical care (SMC)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Standardised medical care (SMC) alone
Number of subjects: 298
Study: 23797954

Group type: EXPERIMENTAL
Intervention: Oral ascorbic acid (AA) 4 g/d
Number of subjects: 110

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 110
Study: 21793327

Group type: EXPERIMENTAL
Intervention: Swimming training for 1 year
Number of subjects: 23
Study: 18821990

Group type: EXPERIMENTAL
Intervention: Orthodontically moved teeth (29 premolars)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control teeth (19 premolars)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Experimental teeth (29 premolars)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Rx method
Number of subjects: 16
Study: 16611512

Group type: COMPARATOR
Intervention: Full-training group (n = 87 patients)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Focus group only group (n = 30 cases)
Number of subjects: 87
Study: 14581270

Group type: EXPERIMENTAL
Intervention: Letrozole as first-line therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen as first-line therapy
Number of subjects: 0
Study: 10973651

Group type: EXPERIMENTAL
Intervention: GnRH agonist (goserelin, 3.6 mg every 4 weeks) plus oral placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: GnRH agonist (goserelin, 3.6 mg every 4 weeks) plus oral continuous combined estradiol-norethisterone acetate add-back therapy daily for 24 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 9356108

Group type: EXPERIMENTAL
Intervention: 1.5% lidocaine in dextrose 7.5% in water
Number of subjects: 51

Group type: COMPARATOR
Intervention: 5% lidocaine in dextrose 7.5% in water
Number of subjects: 51
Study: 8260566

Group type: EXPERIMENTAL
Intervention: 3 mg of haloperidol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 150 mg of remoxipride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 4087695

Group type: EXPERIMENTAL
Intervention: Regular dialysis
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isolated ultrafiltration
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Regular dialysis and isolated ultrafiltration
Number of subjects: 30
Study: 31321951

Group type: EXPERIMENTAL
Intervention: Real transcranial direct current stimulation (2 mA) over Broca's area
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Real transcranial direct current stimulation (2 mA)
Number of subjects: 16
Study: 29889750

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 27634316

Group type: EXPERIMENTAL
Intervention: Mental practice training
Number of subjects: 12

Group type: COMPARATOR
Intervention: Self-directed textbook study (Control)
Number of subjects: 12
Study: 24549267

Group type: EXPERIMENTAL
Intervention: SonoVue
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study: 23237456

Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Enhanced Care as Usual (ECAU)
Number of subjects: 1000
Study: 20380750

Group type: EXPERIMENTAL
Intervention: Traumeel tablets
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 18795697

Group type: EXPERIMENTAL
Intervention: Indocyanine green plasma disappearance rate (PDR(ICG))
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Prothrombin time (PT)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Bilirubin
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: PDR(ICG)
Number of subjects: 96
Study: 16131466

Group type: EXPERIMENTAL
Intervention: Subcutaneous block
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Metacarpal block
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Transthecal block
Number of subjects: 50
Study: 12704016

Group type: EXPERIMENTAL
Intervention: Single counseling session targeting problem areas (condom use, negotiation, disclosure)
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Single-session comprehensive intervention covering all 3 intervention domains
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Comprehensive intervention plus 2 monthly booster sessions
Number of subjects: 387

Group type: COMPARATOR
Intervention: 3-session diet and exercise attention-control condition
Number of subjects: 387
Study: 10370741

Group type: EXPERIMENTAL
Intervention: Renal dipeptidase activity in urine (U/mol creatinine)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Urinary excretion of dipeptidase (U/mmol creatinine)
Number of subjects: 43
Study: 7526483

Group type: EXPERIMENTAL
Intervention: Ischaemic heart disease (IHD) patients
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Peripheral vascular disease (PVD) patients
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: All subjects
Number of subjects: 83

Group type: COMPARATOR
Intervention: All patients and controls
Number of subjects: 83
Study: 2690621

Group type: EXPERIMENTAL
Intervention: Ofloxacin, 400 mg orally every 12 hours
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cefotaxime, 2.0 g intravenously every eight hours
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 1101933

Group type: EXPERIMENTAL
Intervention: Intensive cyclical combination chemotherapy (CVP)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Total body radiation therapy
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Nodular lymphoma
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Diffuse lymphoma
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Complete remission
Number of subjects: 65
Study: 31809866

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (100,000 IU)
Number of subjects: 5110
Study: 30267930

Group type: EXPERIMENTAL
Intervention: Daily bathing with 4% chlorhexidine gluconate followed by water rinsing (CHGwr)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Daily bathing with standard soap (Control)
Number of subjects: 449
Study: 28573374

Group type: EXPERIMENTAL
Intervention: TRPV1 and TRPA1 activators
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 25912697

Group type: EXPERIMENTAL
Intervention: Serelaxin 30 µg·kg(‐1)·day(‐1)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Serelaxin 10 µg·kg(‐1)·day(‐1)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 24369097

Group type: EXPERIMENTAL
Intervention: Computed tomographic coronary angiography (CTA)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Invasive coronary angiography (ICA)
Number of subjects: 250
Study: 20710133

Group type: EXPERIMENTAL
Intervention: Exercise supported by The Coach Approach (CA)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Personal demonstration and follow up of exercise methods (EX)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Exercise suggested through written information only (INFO)
Number of subjects: 53
Study: 17206496

Group type: EXPERIMENTAL
Intervention: dynamic vacuum orthosis with permitted mobilisation to 10 degrees ‐0 degrees ‐10 degrees at the ankle joint
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: dynamic vacuum orthosis
Number of subjects: 27

Group type: COMPARATOR
Intervention: synthetic cast
Number of subjects: 27
Study: 16336518

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg) for 16 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo for 16 weeks
Number of subjects: 17
Study: 14686563

Group type: EXPERIMENTAL
Intervention: Rivastigmine 6-12 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10979055

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control to levels lower than 130/85 mm Hg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, calcium antagonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, calcium antagonists
Number of subjects: 0
Study: 9364091

Group type: EXPERIMENTAL
Intervention: Stabilisation splint worn 24 hours/day
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Stabilisation splint worn only during the day
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Stabilisation splint worn only at night
Number of subjects: 70
Study: 1397666

Group type: EXPERIMENTAL
Intervention: Nicardipine hydrochloride/HCTZ (30 mg nicardipine three times daily)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Pindolol/HCTZ (5 mg pindolol three times daily)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Nicardipine hydrochloride/HCTZ
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both treatments (Nicardipine/HCTZ and Pindolol/HCTZ)
Number of subjects: 43
Study: 3925630

Group type: EXPERIMENTAL
Intervention: Simultaneous administration of vinblastine, thiotepa, and 5-fluorouracil once a week
Number of subjects: 58

Group type: COMPARATOR
Intervention: Sequential administration of vinblastine on days 1 and 2, thiotepa on day 3, and 5-fluorouracil on day 5, weekly
Number of subjects: 58
Study: 31618208

Group type: EXPERIMENTAL
Intervention: Intensive anthelminthic treatment
Number of subjects: 2881

Group type: COMPARATOR
Intervention: HIV infected individuals on cART
Number of subjects: 2881
Study: 30221885

Group type: EXPERIMENTAL
Intervention: EPNs from Semarang isolate
Number of subjects: 0

Group type: COMPARATOR
Intervention: EPNs from commercial biopesticide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EPNs from Semarang isolate and commercial biopesticide
Number of subjects: 0
Study: 26321288

Group type: EXPERIMENTAL
Intervention: OBV/PTV/r+DSV+RBV
Number of subjects: 459

Group type: COMPARATOR
Intervention: TPV+PegIFN/RBV
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: OBV/PTV/r+DSV
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: OBV/PTV/r+DSV±RBV
Number of subjects: 459
Study: 23844826

Group type: EXPERIMENTAL
Intervention: Protective creams (PCs) applied at a low dose (2 mg/cm²)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Protective creams (PCs) applied at a high dose (20 mg/cm²)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Unprotected test sites
Number of subjects: 20
Study: 22992160

Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 20479532

Group type: EXPERIMENTAL
Intervention: Comprehensive strength and endurance exercise program (12 weeks, 36 sessions, starting 4 to 6 weeks post-surgery)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Comprehensive strength and endurance exercise program
Number of subjects: 48
Study: 18047870

Group type: EXPERIMENTAL
Intervention: Social communication skills training (12 weekly group sessions, 1.5 hours each)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Social communication skills training
Number of subjects: 52
Study: 15919393

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (100 microg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intracervical Foley catheter
Number of subjects: 100
Study: 12177793

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa at doses of 0.5 to 8.0 m.c.g x kg(‐1) x wk(‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 3.0 to 9.0 m.c.g x kg(‐1) every 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Epoetin alfa at an initial dose of 150 U x kg(‐1) three times weekly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Epoetin alfa at an initial dose of 40,000 U x wk(‐1)
Number of subjects: 0
Study: 10023731

Group type: EXPERIMENTAL
Intervention: Nutrition, cognitive-behavioral obesity treatment plus exercise
Number of subjects: 39

Group type: COMPARATOR
Intervention: Navy's usual treatment (exercise alone)
Number of subjects: 39
Study: 7589031

Group type: EXPERIMENTAL
Intervention: Zileuton 200 mg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Zileuton 400 mg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Zileuton 600 mg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Population typical values for a 70-kg person
Number of subjects: 37
Study: 2025841

Group type: EXPERIMENTAL
Intervention: Standardized external radiation therapy to the pelvis or to the pelvis and para-aortic lymph nodes followed by one or two brachytherapy applications
Number of subjects: 626
Study: 6404636

Group type: EXPERIMENTAL
Intervention: Activated charcoal 50 g
Number of subjects: 6

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 6
Study: 31931977

Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric band (LAGB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1-year diabetes and weight management (DWM)
Number of subjects: 40
Study: 29738286

Group type: EXPERIMENTAL
Intervention: Self-limiting excavation protocol using chemomechanical Carisolv gel/operating microscope
Number of subjects: 86

Group type: COMPARATOR
Intervention: Selective removal to leathery dentin using rotary burs (control)
Number of subjects: 86
Study: 26822592

Group type: EXPERIMENTAL
Intervention: Tai-chi
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 153

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 153
Study: 25117817

Group type: EXPERIMENTAL
Intervention: Concurrent trastuzumab (Arm C)
Number of subjects: 1365

Group type: COMPARATOR
Intervention: Sequential trastuzumab after chemotherapy (Arm B)
Number of subjects: 1365

Group type: COMPARATOR
Intervention: Chemotherapy alone (Arm A)
Number of subjects: 1365

Group type: COMPARATOR
Intervention: Validation cohort (n=130)
Number of subjects: 1365
Study: 22300946

Group type: EXPERIMENTAL
Intervention: Zidovudine (AZT)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 15

Group type: COMPARATOR
Intervention: HIV treatment-naive patients
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Overall gene expression across all treatment groups
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: EFV-containing ARV regimens
Number of subjects: 15
Study: 20465647

Group type: EXPERIMENTAL
Intervention: Short pulse (SP) 0.3 ms
Number of subjects: 24

Group type: COMPARATOR
Intervention: Super-long pulse (SL) 250 ms
Number of subjects: 24
Study: 18045299

Group type: COMPARATOR
Intervention: Bupivacaine alone (n = 17)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Bupivacaine + sufentanil (n = 16)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups (Bupivacaine alone and Bupivacaine + sufentanil)
Number of subjects: 33
Study: 16142594

Group type: EXPERIMENTAL
Intervention: Fluvastatin, 80 mg, p.o.
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 11864920

Group type: EXPERIMENTAL
Intervention: Abciximab for 24 hours
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Abciximab for 48 hours
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study: 10204904

Group type: EXPERIMENTAL
Intervention: Lidocaine/prilocaine cream applied for 60 minutes
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 60
Study: 8849538

Group type: EXPERIMENTAL
Intervention: Unsutured 6 mm frown incisions
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sutured 6 mm frown incisions
Number of subjects: 30
Study: 2097777

Group type: EXPERIMENTAL
Intervention: Captopril with furosemide and propranolol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Enalapril with furosemide and propranolol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 40
Study: 202205

Group type: EXPERIMENTAL
Intervention: Halothane anesthesia
Number of subjects: 11

Group type: COMPARATOR
Intervention: General anesthesia without halothane
Number of subjects: 11
Study: 31196453

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 27454
Study: 27429350

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 25663767

Group type: EXPERIMENTAL
Intervention: Xiaotan Sanjie (XTSJ) decoction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interleukin-8 (IL-8)
Number of subjects: 0
Study: 23549582

Group type: EXPERIMENTAL
Intervention: V710 vaccine, 60 μg (n = 4015)
Number of subjects: 8031

Group type: COMPARATOR
Intervention: Placebo (n = 4016)
Number of subjects: 8031
Study: 22400901

Group type: EXPERIMENTAL
Intervention: Best medical care plus intermittent pneumatic compression
Number of subjects: 2800

Group type: COMPARATOR
Intervention: Best medical care
Number of subjects: 2800
Study: 19494217

Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg subcutaneously every 8 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 35
Study: 17962502

Group type: EXPERIMENTAL
Intervention: 12-minute visit from a volunteer with a therapy dog
Number of subjects: 76

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 76

Group type: COMPARATOR
Intervention: 12-minute visit from a volunteer
Number of subjects: 76
Study: 15121733

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) 5000 U/day plus low-dose aspirin
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no treatment intervention)
Number of subjects: 55
Study: 11436644

Group type: EXPERIMENTAL
Intervention: Lamivudine
Number of subjects: 72
Study: 9580193

Group type: EXPERIMENTAL
Intervention: Couples with successive failed IVF cycles (group 1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Infertile couples achieving a viable pregnancy with their first IVF attempt (group 2)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Population sample (group 3)
Number of subjects: 50
Study: 7873221

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 50
Study: 2979272

Group type: EXPERIMENTAL
Intervention: BRL 24924 (2.2 mg single oral dose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31558480

Group type: EXPERIMENTAL
Intervention: Cabozantinib (arm 1)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Temozolomide or Dacarbazine (arm 2)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Cabozantinib after progression (arm 2X)
Number of subjects: 46
Study: 30197142

Group type: EXPERIMENTAL
Intervention: Inoculation with 3 × 10^9 cfu of Mannheimia haemolytica (MH) suspended in 5 mL of sterile phosphate buffered saline (PBS) followed by a 120 mL wash PBS (n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Inoculation with 5 mL + 120 mL of sterile PBS (control; n = 12)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Inoculation with 3 × 10^9 cfu of Mannheimia haemolytica (MH)
Number of subjects: 24
Study: 27459375

Group type: EXPERIMENTAL
Intervention: Exercise training (n = 46)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control (standard maternity care, n = 45)
Number of subjects: 91
Study: 24902453

Group type: EXPERIMENTAL
Intervention: Increased tidal volumes with larger apparatus dead space (DS group, 15 patients)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Positive end-expiratory pressure (PEEP, 15 patients)
Number of subjects: 30
Study: 23753094

Group type: EXPERIMENTAL
Intervention: Web-based counselor-assisted problem solving (CAPS) intervention
Number of subjects: 132

Group type: COMPARATOR
Intervention: Internet resource comparison (IRC)
Number of subjects: 132
Study: 20545838

Group type: EXPERIMENTAL
Intervention: Mid-afternoon nap (14:00-16:00 hours)
Number of subjects: 21

Group type: COMPARATOR
Intervention: No nap (control group)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Sleep loss
Number of subjects: 21
Study: 18543304

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 60
Study: 15718847

Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once-weekly plus dietary counselling
Number of subjects: 25

Group type: COMPARATOR
Intervention: Diet counselling alone
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once-weekly
Number of subjects: 25
Study: 12358250

Group type: EXPERIMENTAL
Intervention: Bran (15 g b.i.d.)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bran
Number of subjects: 12
Study: 10327492

Group type: EXPERIMENTAL
Intervention: Tennis players
Number of subjects: 633

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 633
Study: 8566253

Group type: EXPERIMENTAL
Intervention: Carbon dioxide
Number of subjects: 157

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 157
Study: 2007377

Group type: EXPERIMENTAL
Intervention: 1000 mg aspirin daily (group 1)
Number of subjects: 79

Group type: COMPARATOR
Intervention: 100 mg aspirin daily (group 2)
Number of subjects: 79
Study: 7036708

Group type: EXPERIMENTAL
Intervention: Diltiazem (120 mg/day and 240 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Open label diltiazem therapy
Number of subjects: 12
Study: 30680828

Group type: EXPERIMENTAL
Intervention: Bimonthly administration of Cetuximab at 500 mg/m2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weekly administration of Cetuximab at 250 mg/m2
Number of subjects: 0
Study: 27135752

Group type: EXPERIMENTAL
Intervention: 6-week rehabilitative CRF self-management exercise intervention
Number of subjects: 72

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 72
Study: 27645341

Group type: EXPERIMENTAL
Intervention: Daclizumab 150mg or 300mg monthly
Number of subjects: 2236
Study: 24472402

Group type: EXPERIMENTAL
Intervention: SB-705498 12 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 22820409

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR) program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Wait-List control group
Number of subjects: 40